Compare Deutsche Bank AG (DB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs GeneDx Holdings Corp — how do they compare? Deutsche Bank AG trades at $36 (market cap $68.51B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Deutsche Bank AG is far larger — about 37× GeneDx Holdings Corp's market cap, and Deutsche Bank AG pays a 3.26% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| DB | WGS | |
|---|---|---|
Market Cap | $68.51B | $1.85B |
Sector | Financials | Technology |
52-Week High | $40.33 | $167.51 |
52-Week Low | $28.37 | $34.51 |
Dividend Yield | 3.26% | — |
Enterprise Value | — | $1.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $35.24, down 1.48% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock shows attractive valuation metrics with a P/E of 9.79 and P/B of 0.76. Recent quarterly earnings have consistently beaten expectations, and the company announced a $1.00 dividend for H1-26. However, 2024 cash flow was negative $33.10 billion, though it improved to a positive $7.6 billion in 2025.
The outlook is mixed; strong profitability and earnings beats support upside, but regulatory scrutiny and volatile cash flows pose risks. Analyst consensus is cautious with 57.58% hold ratings. The stock's low valuation may appeal to value investors, yet headline risks from recent legal searches require monitoring.
GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.
Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
